|
 Donald Trump and Joe Biden are preparing to face off next week in the first of three presidential debates, as a Supreme Court vacancy supercharges the election season and the U.S. continues to grapple with the coronavirus pandemic.
|
|
 (Bloomberg) -- Novavax Inc. climbed as much as 6.7% in extended trading on plans to start enrolling participants for a late-stage study of its experimental shot for the novel coronavirus in 10,000 patients in the U.K.The company joins the ranks of AstraZeneca Plc, Pfizer Inc. with German partner BioNTech SE and Moderna Inc. as its vaccine enters the final stretch on the path toward regulatory approval. There are roughly 38 shots being tested in humans around the world and more than 140 others in earlier stages of study, according to the World Health Organization's estimates.Half of the people enrolled in Novavax's placebo-controlled trial will get two shots of NVX-CoV2373 with Matrix-M, the biotech company's adjuvant meant to make the immunizing shot more powerful. At least a quarter of study participants will be seniors, and priority will be given to enrolling racial and ethnic minorities hardest hit by the virus.The study has a two-pronged target to show effectiveness in those with symptoms of the disease or in moderate to severe Covid-19 patients, and achieving either goal may be enough to get a regulatory nod. Up to 400 people in the study will also get a seasonal flu vaccine to gauge the potential of administering a Covid shot alongside a flu shot.Novavax shares rose as much as 6.7% to $109.31 in postmarket trading in New York. The Gaithersburg, Maryland-based company secured a $1.6 billion U.S. contract in July on top of $388 million in funding from the Coalition for Epidemic Preparedness Innovations in May.
|
|
Walmart, Target and 1-800-Flowers.com are among the companies taking on workers for the holiday shopping season.
|
RELATED ARTICLES | | |
|
Private Label